预约演示

更新于：2025-05-07

Lymphoma DNA vaccine(Genvax)

更新于：2025-05-07

概要

概要

基本信息

药物类型

DNA疫苗、治疗性疫苗

别名

Lymphoma DNA vaccine、Lymphoma vaccine (idiotypic)

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症-

非在研适应症

淋巴瘤

原研机构

Genvax Technologies, Inc

在研机构-

非在研机构

Genvax Technologies, Inc

权益机构-

最高研发阶段终止临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 Lymphoma DNA vaccine(Genvax) 相关的临床结果

登录后查看更多信息

100 项与 Lymphoma DNA vaccine(Genvax) 相关的转化医学

登录后查看更多信息

100 项与 Lymphoma DNA vaccine(Genvax) 相关的专利（医药）

登录后查看更多信息

项与 Lymphoma DNA vaccine(Genvax) 相关的文献（医药）

2018-11-15·Nature

Building a better lymphoma vaccine

Article

作者: Ainsworth, Claire

Researchers are closing in on vaccines to prevent or treat lymphomas and other cancers triggered by the Epstein-Barr virus.

2012-06-01·Seminars in Oncology3区 · 医学

Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial

3区 · 医学

Review

作者: Sheeba Koshy Thomas ; Larry W. Kwak

Many of the efforts toward developing vaccines against human malignancies have been frustrated by the lack of identification of a tumor-specific antigen that would allow tumor cells to be distinguished from normal cells. Idiotypic determinants of the surface immunoglobulin (Ig) associated with a given patient's B-cell lymphoma are unique to that tumor, and can thus serve as a tumor-specific marker. When conjugated to the immune carrier keyhole limpet hemocyanin (KLH), vaccination with an idiotype protein vaccine has been able to improve length of freedom from disease relapse in patients with follicular lymphoma (FL) in a minimal residual disease (MRD) state after induction therapy, as demonstrated in a recent randomized, controlled phase III trial. In addition to predictive biomarker discovery, using residual autologous tumor and blood samples from patients vaccinated on the phase III trial, we have now developed a next generation idiotype DNA vaccine with the goal of reducing vaccine production time while maintaining efficacy. A first-in-human study is planned to evaluate its use in patients with asymptomatic phase lymphoplasmacytic lymphoma.

2012-03-01·Blood1区 · 医学

Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice

1区 · 医学

Article

作者: Dickinson, Robert ; Carlring, Jennifer ; Heath, Andrew W. ; De Leenheer, Evy ; Szabo, Marika J.

AbstractPersonalized immunotherapy of lymphoma based on tumor idiotype (Id) has shown anti-idiotype humoral immune responses in 40%-50% and cellular immune responses in 50%-75% of follicular lymphoma patients, indicating that this therapy can be clinically successful. We have developed a novel vaccine against lymphoma consisting of an anti-CD40 Ab (ADX40) chemically conjugated to the tumor idiotype A20 and tested it in a murine lymphoma model. BALB/c mice were immunized with 2 doses of immunogen alone or in conjunction with additional adjuvants before tumor challenge. ADX40-Id vaccination resulted in significantly retarded tumor growth and reduced mouse morbidity. Moreover, similar mouse survival was obtained with 2 injections of ADX40-Id as with 8 injections using the standard therapy of keyhole limpet hemocyanin Id + GM-CSF. Co-administration of ADX40-Id with 3-O-deacyl-4′-monophosphoryl lipid A further significantly enhanced vaccine efficacy, resulting in an increased overall survival. Anti-Id–specific Abs were detected at elevated levels after ADX40-Id immunization; however, in vivo depletion of CD4 and/or CD8 T cells before challenge showed that CD8 effector T cells were the major mediators of tumor protection. The results of the present study show that the ADX40-Id conjugate vaccine is a potential candidate as a stand-alone vaccine or in combination with currently licensed adjuvants for lymphoma immunotherapy.

100 项与 Lymphoma DNA vaccine(Genvax) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
淋巴瘤	临床2期	英国	Genvax Technologies, Inc	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2004	N/A	滤泡性淋巴瘤	155	idiotypic vaccination (Humoral anti-Id IR)	(網淵鑰壓夢夢築餘壓選): relative benefit = 2.45 (95% CI, 1.5 ~ 4.0), P-Value = 0.0004	-	2004-07-15
				idiotypic vaccination (Cellular anti-Id IR)